Latest Headlines

Latest Headlines

Lilly sales reel from Zyprexa loss, but Cymbalta offers aid

Eli Lilly wasn't alone in reporting a big decline in sales and a drop in profits this quarter. It's the only Big Pharma today, however, whose earnings didn't disappoint analysts. Thanks to unexpectedly strong growth for the antidepressant Cymbalta, profits fell less than expected--23% to $924 million.

Shire one of many injured in patent free-for-all

The market is showing its own hypersensitivity to the ongoing onslaught of generics on the the world's best-selling drugs.

Feds nab suspects in $70M Lilly heist

The feds say the 23 suspects are tied to pharmaceutical cargo losses worth tens of millions of dollars throughout the country.

Lilly hunkers down for lean years with salary freeze

Eli Lilly ($LLY), languishing in the doldrums of its long-expected "Years YZ," has frozen the salaries of many of its staffers, including those of top management. As Pharmalot reports, the company

Pfizer, Lilly earnings drop on new generic rivals

Pfizer ($PFE) and Eli Lilly ($LLY) are continuing the downward-sloping earnings trend that's dominated Big Pharma's fourth-quarter reports. Pfizer saw profits drop by half, while Lilly's earnings

Lilly surprises with lower-than-expected 2012 forecast

Eli Lilly ($LLY) has long been warning about a yearslong sales trough, and those years have officially arrived. But the company says it's now projecting a deeper-than-expected drop in profits for

Alexza layoffs looming

Alexza Pharmaceuticals may be literally going for broke as it pursues approval of its inhaled fast-acting antipsychotic drug Adasuve. The company ($ALXA) announced that it will pursue significant,

Teva jacks up prices on Cephalon legacy brands

Here's one way to increase your drug sales overnight: First, buy a company. Then, raise its product prices up to 25%. That, apparently, is Teva Pharmaceutical Industries' ($TEVA) strategy for

Ireland's exports set to fall off the patent cliff

The patent cliff is like a yurt. It has many sides. To Big Pharma, it's been a looming threat for years. To generics makers, it's a multibillion-dollar boon. To India, with its generics-heavy pharma

Antipsychotics, ADHD meds fuel rising psych-drug use

With sales figures showing that individual psych meds are among Big Pharma's best sellers--think Eli Lilly's ($LLY) Zyprexa, for one--it's no surprise to see the percentage of Americans using drugs